HY Capital

HY Capital is a venture capital firm established in 2015 and based in Shanghai, China. The firm focuses on the healthcare industry, specializing in early-stage and growth-stage investments. By targeting innovative companies within the healthcare sector, HY Capital aims to support the development of new technologies and solutions that can improve patient care and health outcomes.

Feng Cao Ph.D

Founding Partner

Yun Liu Ph.D

Founding Partner and Chairman of the Board

20 past transactions

Only Sanbio

Seed Round in 2025
Only Sanbio is a synthetic biotechnology company integrating R&D, production, and sales. Itsmed vision is to focus on the field of great health and great beauty, based on synthetic biology technology

Linyan Medical

Venture Round in 2025
Linyan Medical is a high-tech company focusing on the combination of man and machine in metaverse medical surgery.

Kang Ruijian

Seed Round in 2025
Kang Ruijian is a developer of thermosensitive modified chitin hydrogel technology.

Onico Medical

Seed Round in 2025
Onico Medical is a medical device developer. The core team comes from the serious medical field and has absorbed professionals with rich experience in medical aesthetics development.

Sylvanus Gene

Angel Round in 2023
Sylvanus Gene is a gene technology company that focuses on R&D and the production of molecular diagnostic equipment for pathogenic microorganisms.

Biotyx Medical

Series B in 2023
Biotyx Medical specializes in the development and sale of innovative medical devices focused on cardiovascular health. The company manufactures biodegradable vascular materials and stents made from iron, which are designed to be bioabsorbable. These products aim to provide doctors with safe and effective treatment options for patients at affordable prices.

Puncture Robotic

Series A in 2023
Puncture Robotic is a developer of advanced venipuncture robots that facilitate automated blood collection and soft tissue interventions. The company's technology focuses on real-time image navigation to enhance precision in procedures such as percutaneous puncture for thoracoabdominal and pelvic tumors, as well as applications in medical aesthetics. Aiming to support medical institutions, Puncture Robotic provides intelligent and cost-effective robotic solutions that improve operational efficiency and patient care by enabling blood collection and other interventions without the need for human involvement.

Chinagene Tech

Series A in 2022
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Juncell Therapeutics

Series A in 2022
Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

Yijian Health

Seed Round in 2022
Yijian Health operates a one-stop precision medicine service platform based in Shanghai, China. Its core offerings include genetic testing services and Laboratory Information Management System (LIMS) software, providing scientific and professional precision healthcare services.

ChosenMed

Series B in 2020
ChosenMed is a healthcare company specializing in oncology precision medicine, primarily concentrating on early tumor screening and companion diagnosis. The company develops innovative oncology products aimed at the early detection, prevention, and diagnosis of tumors. ChosenMed emphasizes the guidance of targeted medication for solid tumors and the prediction of the efficacy of tumor immunotherapy. By offering a comprehensive suite of precision medical and immunotherapy solutions, the company seeks to enhance patient outcomes in the field of oncology.

Zhizu Tech

Series A in 2019
Zhizu Tech, officially known as Shanghai Zhizu Logistics Technology Co., Ltd., is a Shanghai-based company founded in 2018 that specializes in developing software and services for end-to-end distribution lease providers. The company offers solutions tailored for express delivery firms and food ordering platforms, enabling them to plan and manage their distribution fleets effectively. Its offerings include delivery vehicle rental services, smart battery swaps, and an IoT cloud management platform. Additionally, Zhizu Tech provides offline maintenance services and builds AI-based data systems to enhance vehicle connectivity. By focusing on logistics and delivery, the company aims to streamline operations and improve efficiency in the instant delivery sector.

MFA

Series A in 2019
MFA members say that it is a skin care platform that aims to make more and better skin care products go from the laboratory to the consumer market, so that more people can enjoy the life change caused by skin care.MFA members said that it is a membership-based beauty and e-commerce platform. It is committed to creating a platform model featuring annual membership e-commerce, relying on its own perfect supply chain advantages to create a “closed eye to buy for the public, big-name quality is not expensive. The shopping experience has been recognized by the consumer market and has a wide growing space.

Cloudbreak Therapeutics

Series A in 2018
Cloudbreak Therapeutics LLC, established in 2015 and based in Irvine, California, is a biotechnology company specializing in the development of ocular drugs. It focuses on repurposing approved systemic drugs for eye delivery, aiming to treat glaucoma and pterygium diseases efficiently. The company operates a capital-efficient model, utilizing contract research organizations (CROs) to maximize resources for drug development. Its business strategy involves advancing drug candidates through proof-of-concept Phase II clinical trials and subsequently out-licensing global rights for Phase III trials, registration, and commercialization.

Fushoukang

Series A in 2018
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Fushoukang

Angel Round in 2018
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Laviana Pharma

Series B in 2018
Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

Symbow Medical

Series A in 2017
Symbow Medical Technology specializes in the manufacturing and distribution of innovative medical devices aimed at early tumor diagnosis and minimally invasive treatments. The company develops advanced equipment, including breast imaging systems and MRI and CT guided therapy platforms that utilize optical and electromagnetic tracking techniques. Their product lineup features the Megrez navigation systems and the OPTIMUS dual-modality molecular imaging system, which enhance surgical planning and diagnostic accuracy. Symbow Medical's products are distributed through various channels in China and internationally, positioning the company at the forefront of medical imaging solutions.

UEG Medical

Series A in 2017
UEG Medical specializes in the production and distribution of medical devices. Its portfolio includes dental CT systems, surgical navigation tools, wound healing materials, and disposable trocars.

Shudouzhe

Seed Round in 2016
Shudouzhe is a tool used by business owners to deal with tax and financial issues. Its goal is to assist business owners in resolving fiscal and tax issues. They are dedicated to assisting freelancers and business owners or offering innovative online financial and tax services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.